Alice Melão,  —

The National Institutes of Health (NIH) awarded $7.8 million to researchers at George Washington University to launch a network for improving research, treatment, and education in myasthenia gravis. This will be the first large and organized effort to focus on the disorder, which affects 20 in 100,000…

DAS Therapeutics has acquired GTP-004, an investigational oral treatment for myasthenia gravis, from GT Biopharma, the companies announced. GTP-004 will be named DAS-MG from now on, DAS Therapeutics said on its website. The investigational treatment combines a fixed dose of pyridostigmine — an approved therapy for myasthenia gravis-associated muscle…

Patients with mild myasthenia gravis (MG) but with poorer nerve cell response in initial diagnostic tests are more likely to progress to more aggressive therapy regimens than those with better nerve responses, known as decrement scores. The study “Baseline Decrement in Patients with Mild Myasthenia Gravis Predicts Immunomodulation…

Camurus AB and Ra Pharmaceuticals have signed an agreement to develop and manufacture a long-acting injectable formulation of zilucoplan for patients with complement-mediated disorders, such as generalized myasthenia gravis. Using Camurus’s proprietary FluidCrystal technology, the subcutaneously injected formulation will allow patients with complement-mediated disorders — such as…

Myasthenia gravis and multiple sclerosis (MS) may share immunological features, according to researchers who studied the rare case of a man who developed both illnesses. The case was described in the study “Co-occurrence of multiple sclerosis and myasthenia gravis: A case report and review of…

Almost 90% of patients diagnosed with myasthenia gravis develop other diseases, or comorbidities, while about 70% have treatment-related complications, a review study from India reports. These additional disorders may contribute to a poorer outcome for these people, making early recognition and management of comorbidities essential for improving patient care and overall…

Myasthenia gravis and amyotrophic lateral sclerosis (ALS) may share common underlying cellular mechanisms mediated by anti-LRP4 antibodies, a rare case report into both diseases being diagnosed in an elderly patient suggests. The study, “Late-onset Myasthenia Gravis Accompanied by Amyotrophic Lateral Sclerosis with Antibodies against the Acetylcholine…

Hormones produced by adipose (fat) tissue, called adipokines, can help assess the progression and status of myasthenia gravis, researchers suggest. A team at Medical University of Silesia in Poland assessed the association between the levels of different adipokines and clinical factors that characterize myasthenia gravis. The study, “…

Argenx is one step closer to launching a global Phase 3 trial to evaluate the potential of its therapy candidate efgartigimod (ARGX-113) for generalized myasthenia gravis (gMG). Following feedback from the U.S. Food and Drug Administration in June, the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan…

Mutations in the genetic sequence of the IL4R gene can increase the risk of myasthenia gravis in the Chinese Han population, the world’s largest ethnic group, researchers reported. The finding was part of the study “IL-4Rα Polymorphism Is Associated With Myasthenia Gravis in Chinese Han Population”…